Lung Cancer
Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all lung cancer cases. Find out more about testing and treatment here.
Search
443 Result(s)
September 02, 2020
Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Lung Cancer
Keith and Heather’s Story
Having lost his left lung to cancer, Keith faced a challenging road to recovery but didn’t allow it to limit his lifestyle or ambitions.
Science Stories
T-cell engagers: Reawakening T-cells to fight cancer
Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our T-cell engagers platform and how we are driving innovation to deliver meaningful advances to people with cancer.
Lung Cancer
LUX-Lung 7 & 8 Trials
Interview with Prof Thomas J. Lynch
Science Stories
Transforming the Treatment of Lung Fibrosis through Lung Repair and Regeneration
Matthew Thomas, Head of Immunology & Respiratory Research, Germany, describes how translational science approaches are informing our lung fibrosis research
Pulmonary Fibrosis
Hope for the future of interstitial lung disease (ILD) care
Karen Moor, pulmonologist in training and post-doctoral researcher in interstitial lung diseases (ILDs), shares her advice for aspiring pulmonologists and her hopes for the future of ILD care.
Pulmonary Fibrosis
Living with RA-ILD: Understanding the connection between rheumatoid arthritis and interstitial lung disease
Learn more about this disease and the impact it can have on those living with the condition and their loved ones.
May 15, 2022
Investigational treatment slowed lung function decline in IPF
April 14, 2021
Expansion of Collaboration with MD Anderson to Explore KRAS and TRAILR2 Compounds in Lung Cancer
Science Stories
Targeting HER2 in cancer: The story of zongertinib
Our cancer researchers share insights into the discovery of zongertinib, our investigational HER2 tyrosine kinase inhibitor.
Science Stories
What does it mean to drug cancer’s “big four”?
Learn how Darryl McConnell & his team are tackling one of the biggest scientific conundrums.
Cancer
Why cancer care is personal for us
Find out more about Boehringer Ingelheim’s generational commitment to transforming cancer care.
Science Focus
Oncology and Cancer Immunology
Cancer
The power of patient advocacy in cancer care
Learn more about patient Larry and UICC president Jeff Dunn's commitment to patient empowerment.
Empowering Patients
Taking Cancer on Through Flavour
Simple, nutritious recipes for people with cancer
Science Stories
SIRPα: A New Chapter in Cancer Immunology Research
Boehringer Ingelheim scientists are exploring a research path scientifically less travelled by investigating a new target in the innate immune system
Science Stories
Protein Degraders: Changing the Game in Cancer Drug Discovery
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Science Stories
Taking KRAS Cancer On
Hear from Darryl McConnell, Research Site Head, Vienna, as he describes how we aim to drug all forms of KRAS
April 09, 2019
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
September 21, 2021
Acquisition to advance cancer immunology research
Article
Excellence in innovation | Bioxcellence | Boehringer Ingelheim
Article
Large Scale Cell Facility | Bioxcellence | Boehringer Ingelheim
Science Stories
Targeting MDM2-p53 in cancer: The story of brigimadlin
Our perseverance and passion for science led to the discovery of brigimadlin, our MDM2-p53 antagonist. It is being clinically investigated as a potential treatment for dedifferentiated liposarcoma, a rare cancer with significant unmet needs.
July 27, 2020